Author + information
- Anat Berkovitch,
- Victor Guetta,
- Israel Barbash,
- Noam Fink,
- Ehud Regev,
- Elad Maor,
- Rafael Kuperstein,
- Ehud Raanani,
- Amjad Shalabi,
- Micha Feinberg,
- Elad Asher,
- Amit Segev and
- Paul Fefer
Background: Transcatheter aortic valve replacemant (TAVR) is rapidly becoming the treatment of choice for high-surgical risk patients with symptomatic aortic stenosis. Little is known regarding the outcome of TAVR patients with previous malignancy.
Methods: We investigated 479 patients who underwent TAVR. Subjects were divided into 2 groups: no history of malignancy (N=388) and positive history of malignancy (N=91).
Results: Mean age of the study population was 81±7 of which 52% were men. No major differences in baseline characteristics were found between groups. All-cause mortality was 24% for both groups at a mean follow-up time of 851±629 days. Kaplan Meier survival analysis demonstrated no difference in all-cause mortality between groups. However, sub-analysis showed that patients with malignancy had higher long-term non-cardiovascular mortality rates compared with those without malignancy (figure). Multivariate cox regression analysis showed that while malignancy status did not affect prognosis regarding cardiovascular or overall mortality (HR 0.86 CI 0.52-1.42 p=0.56), it had a strong link to non-cardiovascular long-term mortality (HR 2.6 CI 1.13-6.12 p=0.024).
Conclusions: Patients with malignancy have good overall short- and long-term outcomes following TAVR but do suffer an excess of long-term non-cardiovascular death. Decisions regarding TAVR among oncological patients should be individualized according to their malignancy status and anticipated life expectancy.
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Interventional Cardiology: TAVR 4
Abstract Category: 17. Interventional Cardiology: Aortic Valve Disease
Presentation Number: 1283-139
- 2017 American College of Cardiology Foundation